HEARTCARE-B (06609) surged more than 12%. As of the time of writing, the stock was up 11.54%, trading at HK$56.55, with a turnover of HK$2.8647 million. The company announced that the Group expects to achieve revenue between approximately RMB 400 million and RMB 410 million for the year ending December 31, 2025, representing an increase of at least 43.9% year-on-year, and a pre-tax profit of about RMB 80 million, turning a loss into a profit compared to the previous year. The revenue growth is primarily attributable to the launch of new products and technologies for ischemic stroke and an increased market share of ischemic stroke products; the large-scale commercialization of intracranial stents and increased sales of other hemorrhagic stroke products; and the sustained growth in sales of interventional access products. Furthermore, the Group's effective cost control measures on cost of sales and administrative expenses have reduced the expense ratio. Additionally, HEARTCARE-B announced that the registration application for its self-developed self-expanding intracranial drug-eluting stent has been accepted by the National Medical Products Administration. The self-expanding intracranial drug-eluting stent is used for the treatment of intracranial atherosclerotic stenosis, providing support and opening for narrowed and obstructed lumens, and can effectively prevent in-stent restenosis. Based on publicly available information, there are currently no similar products approved for marketing globally, and the company's R&D progress for this type of product is at a leading level within the industry.